Incyte Corporation (INCY) reported robust third-quarter revenue, exceeding analyst expectations driven by strong demand for its key drug, Jakafi. The company’s optimistic outlook for Jakafi and its pipeline prospects led BofA Securities to upgrade Incyte’s stock to Buy, highlighting the potential for continued growth and multiple catalysts in the coming years.